MX2016011333A - Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. - Google Patents

Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.

Info

Publication number
MX2016011333A
MX2016011333A MX2016011333A MX2016011333A MX2016011333A MX 2016011333 A MX2016011333 A MX 2016011333A MX 2016011333 A MX2016011333 A MX 2016011333A MX 2016011333 A MX2016011333 A MX 2016011333A MX 2016011333 A MX2016011333 A MX 2016011333A
Authority
MX
Mexico
Prior art keywords
gemcitabine
bladder
treatment
methods
drug delivery
Prior art date
Application number
MX2016011333A
Other languages
English (en)
Spanish (es)
Inventor
Lee Heejin
Giesing Dennis
Daniel Karen
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of MX2016011333A publication Critical patent/MX2016011333A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
MX2016011333A 2014-03-06 2015-03-06 Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. MX2016011333A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461949215P 2014-03-06 2014-03-06
PCT/US2015/019262 WO2015134911A1 (en) 2014-03-06 2015-03-06 Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Publications (1)

Publication Number Publication Date
MX2016011333A true MX2016011333A (es) 2016-12-07

Family

ID=52697553

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011333A MX2016011333A (es) 2014-03-06 2015-03-06 Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.

Country Status (24)

Country Link
US (3) US20150250717A1 (enExample)
EP (2) EP4124339B1 (enExample)
JP (5) JP6901858B2 (enExample)
KR (1) KR102338079B1 (enExample)
CN (2) CN119950539A (enExample)
AU (4) AU2015226901B2 (enExample)
BR (1) BR112016020381A8 (enExample)
CA (1) CA2939979C (enExample)
DK (2) DK3113782T3 (enExample)
ES (2) ES3051417T3 (enExample)
FI (1) FI4124339T3 (enExample)
HR (2) HRP20251264T1 (enExample)
HU (1) HUE060704T2 (enExample)
IL (2) IL311410B2 (enExample)
LT (2) LT3113782T (enExample)
MX (1) MX2016011333A (enExample)
PL (2) PL3113782T3 (enExample)
PT (2) PT3113782T (enExample)
RS (2) RS63675B1 (enExample)
RU (1) RU2694902C1 (enExample)
SG (2) SG10202101978SA (enExample)
SI (1) SI4124339T1 (enExample)
SM (2) SMT202200449T1 (enExample)
WO (1) WO2015134911A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036556A2 (en) 2012-08-31 2014-03-06 Taris Biomedical, Inc. Drug delivery systems and methods for treatment of prostate
IL299897B2 (en) 2013-08-19 2024-02-01 Taris Biomedical Llc Devices and methods for administering multiple units of drug
PT3113782T (pt) 2014-03-06 2023-01-05 Taris Biomedical Llc Sistemas e métodos de administração de fármaco para tratamento do cancro da bexiga com gemcitabina
SG11201809838VA (en) * 2016-05-06 2018-12-28 Taris Biomedical Llc Method of treating lower tract urothelial cancer
US10857173B2 (en) * 2017-07-25 2020-12-08 Taris Biomedical Llc Methods of treating tumor metastasis
KR102892737B1 (ko) * 2017-11-08 2025-11-28 타리스 바이오메디컬 엘엘씨 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법
AU2019315957A1 (en) 2018-08-01 2021-02-18 Taris Biomedical Llc Methods of treating overactive bladder using trospium
JP7660066B2 (ja) * 2019-10-03 2025-04-10 生化学工業株式会社 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム
RU2713443C2 (ru) * 2019-11-01 2020-02-05 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения мышечно-инвазивного рака мочевого пузыря т3-т4 n0-+m0
JP2023512652A (ja) * 2020-01-27 2023-03-28 アイソラ セラピューティクス,インコーポレイテッド 管腔内局所薬剤送達のための組織内投与
CN112169066B (zh) * 2020-10-29 2023-05-12 安徽省立医院(中国科学技术大学附属第一医院) 具有控制器的连续缓释给药留置管
CN113616666A (zh) * 2021-08-24 2021-11-09 傅广波 膀胱黏膜下注射吉西他滨在治疗膀胱癌中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US6171298B1 (en) 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
CA2432438C (en) 2001-01-09 2011-04-26 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
US7534241B2 (en) * 2002-09-23 2009-05-19 Microchips, Inc. Micro-reservoir osmotic release systems and microtube array device
US20040260272A1 (en) 2002-10-22 2004-12-23 Friedman Craig D. Method and system for intravesicular delivery of therapeutic agents
CA2520610A1 (en) * 2003-03-31 2004-10-21 Alza Corporation Osmotic pump with means for dissipating internal pressure
US8361490B2 (en) * 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
EP1933810B1 (en) 2005-08-11 2012-10-10 Massachusetts Institute of Technology Intravesical drug delivery device and method
CA2649877A1 (en) * 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
EA201070703A1 (ru) 2007-12-11 2010-12-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарства и способы лечения мочевого пузыря и других полостей тела или трубчатых органов
JP5538359B2 (ja) 2008-04-04 2014-07-02 リペラ ファーマシューティカルズ, インコーポレイテッド リポソームボツリヌス毒素を使用する膀胱機能障害の治療
EP2313122B1 (en) 2008-07-17 2019-03-06 Micell Technologies, Inc. Drug delivery medical device
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
CA2765630C (en) 2009-06-26 2016-07-05 Taris Biomedical, Inc. Solid drug tablets for implantable drug delivery devices
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
AU2010339821B2 (en) 2009-12-17 2015-02-19 Taris Biomedical Llc Implantable device with intravesical tolerability and methods of treatment
EP2525777B1 (en) * 2010-01-20 2019-05-29 UroGen Pharma Ltd. Material and method for treating internal cavities
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
JP2013527232A (ja) 2010-06-02 2013-06-27 アブラクシス バイオサイエンス, エルエルシー 膀胱がんの処置方法
US9492266B2 (en) 2010-08-05 2016-11-15 Taris Biomedical Llc Ureteral stent drug delivery device, kit, and method
WO2012048104A1 (en) 2010-10-06 2012-04-12 Taris Biomedical, Inc. Implantable drug delivery device with bladden retention feature
WO2012048114A1 (en) 2010-10-06 2012-04-12 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
EA035494B1 (ru) 2010-10-27 2020-06-25 Прометик Фарма Смт Лимитед Способ и применение композиции для ингибирования миграции клеток опухоли и образования метастазов
US8979797B2 (en) 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
JP2014503554A (ja) 2011-01-10 2014-02-13 タリス バイオメディカル,インコーポレイテッド 膀胱痛及び刺激性排尿の持続的治療の使用のためのリドカインレジメン
ES2637388T3 (es) * 2011-02-04 2017-10-13 Taris Biomedical, Inc. Dispositivo implantable para la liberación controlada de un fármaco de baja solubilidad
US20150005595A1 (en) 2011-12-30 2015-01-01 Kibur Medical, Inc. Implantable devices and methods for evaluation of active agents
KR20190134832A (ko) 2012-03-29 2019-12-04 알토 바이오사이언스 코포레이션 종양 형성 치료방법
US10058688B2 (en) 2012-05-09 2018-08-28 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
WO2014036556A2 (en) * 2012-08-31 2014-03-06 Taris Biomedical, Inc. Drug delivery systems and methods for treatment of prostate
PL2890384T3 (pl) 2012-08-31 2022-02-14 Taris Biomedical Llc Układy podawania leku i sposoby leczenia raka pęcherza obejmujące oksaliplatynę
EP2897616A1 (en) 2012-09-18 2015-07-29 TARIS Biomedical LLC Drug delivery systems and methods for treatment of bladder voiding dysfunction!and other lower urinary tract disorders by using trospium
JP2016508842A (ja) 2013-03-05 2016-03-24 タリス バイオメディカル エルエルシー 装置の開口部を通じて制御された薬物放出のための薬物送達装置及び方法
PL2968880T3 (pl) 2013-03-15 2025-06-23 Taris Biomedical Llc Urządzenia do dostarczania leku ze składnikiem przepuszczalnym dla leku
MX391755B (es) 2013-03-15 2025-03-21 Taris Biomedical Llc Dispositivos de administración de medicamentos y métodos para administración de medicamentos.
JP6431528B2 (ja) 2013-04-10 2018-11-28 マサチューセッツ インスチテュート オブ テクノロジーMassachusetts Institute Of Technology 癌治療のための薬物局所送達装置及び方法
IL299897B2 (en) * 2013-08-19 2024-02-01 Taris Biomedical Llc Devices and methods for administering multiple units of drug
BR112016010103A8 (pt) * 2013-11-05 2018-01-30 Taris Biomedical Llc métodos, kits e dispositivos de suprimento de fármaco osmótico.
PT3113782T (pt) 2014-03-06 2023-01-05 Taris Biomedical Llc Sistemas e métodos de administração de fármaco para tratamento do cancro da bexiga com gemcitabina
RU2591946C2 (ru) 2014-06-24 2016-07-20 Владимир Эдуардович Анников Способ изготовления гелеобразного водосодержащего взрывчатого состава
KR20230142816A (ko) 2014-06-26 2023-10-11 타리스 바이오메디컬 엘엘씨 탄성 폴리머-약물 매트릭스 시스템을 포함하는 방광내 약물 전달 장치 및 방법
EP4744688A2 (en) 2015-04-23 2026-05-20 Janssen Biotech Inc DRUG DELIVERY DEVICES WITH A DRUG-PERMEABLE COMPONENT AND METHODS
SG11201809838VA (en) 2016-05-06 2018-12-28 Taris Biomedical Llc Method of treating lower tract urothelial cancer
US10857173B2 (en) 2017-07-25 2020-12-08 Taris Biomedical Llc Methods of treating tumor metastasis
KR102892737B1 (ko) 2017-11-08 2025-11-28 타리스 바이오메디컬 엘엘씨 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법
AU2019315957A1 (en) 2018-08-01 2021-02-18 Taris Biomedical Llc Methods of treating overactive bladder using trospium

Also Published As

Publication number Publication date
AU2022215156B2 (en) 2024-09-05
PL4124339T3 (pl) 2025-11-17
RS63675B1 (sr) 2022-11-30
JP7383681B2 (ja) 2023-11-20
SG11201607342QA (en) 2016-10-28
IL247347B2 (en) 2025-03-01
RU2694902C1 (ru) 2019-07-18
DK3113782T3 (da) 2022-10-17
US20220347091A1 (en) 2022-11-03
ES3051417T3 (en) 2025-12-29
JP2024009034A (ja) 2024-01-19
US20150250717A1 (en) 2015-09-10
EP3113782A1 (en) 2017-01-11
US12582599B2 (en) 2026-03-24
AU2024259822A1 (en) 2024-11-28
EP4124339B1 (en) 2025-09-10
US20220117886A1 (en) 2022-04-21
FI4124339T3 (fi) 2025-10-17
SMT202500385T1 (it) 2025-11-10
IL311410B2 (en) 2025-11-01
CA2939979A1 (en) 2015-09-11
AU2015226901A1 (en) 2016-09-01
PT3113782T (pt) 2023-01-05
AU2022215156A1 (en) 2022-09-01
JP2019218410A (ja) 2019-12-26
IL247347A0 (en) 2016-11-30
CA2939979C (en) 2023-03-21
JP6901858B2 (ja) 2021-07-14
ES2930435T3 (es) 2022-12-13
DK4124339T3 (da) 2025-10-13
LT3113782T (lt) 2022-11-25
WO2015134911A1 (en) 2015-09-11
IL311410A (en) 2024-05-01
KR20160124425A (ko) 2016-10-27
SMT202200449T1 (it) 2023-01-13
HRP20221252T1 (hr) 2022-12-09
RS67337B1 (sr) 2025-11-28
AU2020217383B2 (en) 2022-09-08
JP7061595B2 (ja) 2022-04-28
NZ723303A (en) 2023-10-27
JP7802743B2 (ja) 2026-01-20
AU2020217383A1 (en) 2020-09-03
EP3113782B1 (en) 2022-09-28
BR112016020381A8 (pt) 2018-05-02
AU2015226901B2 (en) 2020-05-14
JP2026062972A (ja) 2026-04-10
HRP20251264T1 (hr) 2025-12-05
SI4124339T1 (sl) 2025-11-28
IL311410B1 (en) 2025-07-01
CN106102751A (zh) 2016-11-09
SG10202101978SA (en) 2021-04-29
JP2022022235A (ja) 2022-02-03
IL247347B1 (en) 2024-11-01
KR102338079B1 (ko) 2021-12-09
PL3113782T3 (pl) 2023-01-23
EP4124339A1 (en) 2023-02-01
LT4124339T (lt) 2025-11-10
BR112016020381A2 (pt) 2017-08-15
HUE060704T2 (hu) 2023-04-28
JP2017508749A (ja) 2017-03-30
CN119950539A (zh) 2025-05-09
PT4124339T (pt) 2025-11-04

Similar Documents

Publication Publication Date Title
BR112016020381A8 (pt) sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina.
MX2020002465A (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros transtornos del tracto urinario inferior.
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
CO2017003263A2 (es) Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12015502266A1 (en) Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
MX379191B (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
MX2022000394A (es) Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.
PH12021552977A1 (en) Methods of treating urinary system cancers
UA118656C2 (uk) Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції
Barsotti CMV lung infection, bladder infection and erythematous rash: 3 case reports
UA116484U (uk) Cпосіб лікування артеріальної гіпертензії з метаболічним синдромом
UA95104U (uk) Спосіб терапії хворих на негоспітальну пневмонію з супутньою хсн
UA82717U (ru) Способ лечения острого ишемического инсульта, обремененного ишемической болезнью сердца
MY203919A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
UA109904C2 (uk) Комбінована терапія для шкірних розладів
UA96488U (uk) Спосіб лікування порушень гемоваскулярного гемостазу у хворих на ішемічну хворобу серця
UA101725U (uk) Спосіб лікування хворих на рак прямої кишки
UA48009U (ru) Способ лечения пациентов с дисфункцией сфинктера одди